Previous 10 | Next 10 |
Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15™ recharge-free sacral neuromodulation (SNM) system in Australia to treat adults with overactive bladder. “Approval ...
2024-05-10 03:35:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Small Cap Fund had a strong first quarter, outperforming the Russell 2000 Growth...
2024-05-03 07:15:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. During the first quarter of 2024, Baron Discovery Fund® (the Fund) was up 4.57% (...
Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2024. “Our commercial team continued to e...
Boston Scientific Announces Results for First Quarter 2024 PR Newswire MARLBOROUGH, Mass. , April 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent o...
2024-04-09 21:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-05 06:42:07 ET Summary Boston Scientific expects 8-10% sales growth in their 2024-2026 guidance, which already includes short-term upsides such as FARAPULSE’s recent FDA approval. The legal clash between Axonics and Medtronic may endanger Boston Scientific's ability...
2024-04-04 08:09:04 ET Boston Scientific’s ( NYSE: BSX ) planned merger with Axonics ( NASDAQ: AXNX ) is now expected to close in the second half of the year after the companies received a request from the U.S. Federal Trade Commission (FTC) for additional informa...
2024-03-22 16:45:21 ET More on Axonics Modulation Technologies Medtronic claims upheld in two patents in spat with Axonics Boston Scientific pulls, refiles HSR notification for Axonics deal Seeking Alpha’s Quant Rating on Axonics Modulation Technologies ...
Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt Axonics’ merger agreement with Boston Scientific Corporation (NYSE: BSX). According to preliminary voting results from the special meeting of stockholders held earlier today, a majority of the shares of ...
News, Short Squeeze, Breakout and More Instantly...
Axonics Modulation Technologies Inc. Company Name:
AXNX Stock Symbol:
NASDAQ Market:
Axonics Modulation Technologies Inc. Website:
Generated record revenue, gross margin and net income in 2Q24 Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results f...
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
AstraZeneca PLC (AZN) is expected to report $0.97 for Q2 2024 BJ's Restaurants Inc. (BJRI) is expected to report $0.49 for Q2 2024 Baker Hughes Company (BKR) is expected to report $0.49 for Q2 2024 BlueHarbor Bank (BLHK) is expected to report for Q2 2024 Betterware de Mexico S.A.P...